News on companion diagnostics and drug/test co-development.
The companies began working together in 2018, when MEDx was known as Qiagen Translational Medicine, on companion and in vitro diagnostics.
Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study.
The company is focused on developing and commercializing therapeutic and companion diagnostic products to treat inflammatory bowel disease.
The new service, slated for launch in the second half of 2021, will allow Myriad to expand its cancer tumor profiling services.
The partners will develop a test to identify women most likely to benefit from VGX-3100, Inovio's immunotherapy to treat HPV-associated advanced cervical dysplasia.
